JUPITER NEUROSCIENCES, INC.
JUNS

NASDAQ > Biotechnology
DCF:$0.07  |   P/E: -
$1.15(11.68%)
Change
Rating:
Price: $9.73 USD
Market Cap: $357.70M

...Loading JUNS Peers...





Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

    4 Employees

    CEO : Mr. Christer Rosen

    Address : 1001 North US HWY 1, Jupiter,FL, US, - 33477,

Key ExcutivesDesignation
Mr. Alexander RosenCo-Founder & Chief Administrative Officer
Mr. Christer RosenCo-Founder, Chief Executive Officer & Chairman of the Board
Ms. Alison D. Silva MA, MSPresident, Chief Business Officer & Director
Dr. Marshall Hayward Ph.D.Co-Founder, Chief Scientific Officer & Director
Mr. Saleem Elmasri CPAChief Financial Officer & Secretary
Dr. Claes Wahlestedt M.D., Ph.D.Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
Dr. Shaun P. Brothers Ph.D.Co-Founder, Consulting Vice President of Scientific Research & Member of Scientific Advisory Board